Free Trial
ASX:GSS

Genetic Signatures (GSS) Stock Price, News & Analysis

Genetic Signatures logo

About Genetic Signatures Stock (ASX:GSS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
A$120.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive GSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Signatures and its competitors with MarketBeat's FREE daily newsletter.

GSS Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Bell Potter Sticks to Its Buy Rating for Genetic Signatures Ltd. (GSS)
Bell Potter Reaffirms Their Buy Rating on Genetic Signatures Ltd. (GSS)
See More Headlines

GSS Stock Analysis - Frequently Asked Questions

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
ASX:GSS
CIK
N/A
Fax
N/A
Employees
1,626
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$17.86 million
Net Margins
-182.90%
Pretax Margin
N/A
Return on Equity
-35.16%
Return on Assets
-19.69%

Debt

Debt-to-Equity Ratio
2.00
Current Ratio
10.04
Quick Ratio
8.54

Sales & Book Value

Annual Sales
A$13.77 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
A$0.29 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
226,870,000
Free Float
N/A
Market Cap
A$120.38 million
Optionable
Not Optionable
Beta
0.05
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (ASX:GSS) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners